Disparate Effects of Stilbenoid Polyphenols on Hypertrophic Cardiomyocytes In Vitro vs. in the Spontaneously Hypertensive Heart Failure Rat
暂无分享,去创建一个
Samuel M. Thomas | Hope D. Anderson | Hope D Anderson | N. Davies | T. Netticadan | M. Majeed | K. Nagabhushanam | P. Raj | Liping Yu | Danielle I. Lee | C. Acosta | H. Anderson | Bolanle C Akinwumi
[1] P. Sachdev,et al. Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer's Disease. , 2016, Current topics in medicinal chemistry.
[2] Benedek Erdos,et al. Age Impaired endothelium-dependent vasodilation is improved by resveratrol in rat mesenteric arteries , 2016, Journal of exercise nutrition & biochemistry.
[3] Kazuki Nakamura,et al. Antitumor activity of melinjo (Gnetum gnemon L.) seed extract in human and murine tumor models in vitro and in a colon-26 tumor-bearing mouse model in vivo , 2015, Cancer medicine.
[4] Hope D. Anderson,et al. Preclinical Pharmacokinetics and Pharmacodynamics and Content Analysis of Gnetol in Foodstuffs , 2015, Phytotherapy research : PTR.
[5] I. M. Robertson,et al. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. , 2015, Biochimica et biophysica acta.
[6] Hope D. Anderson,et al. Ligand Activation of Cannabinoid Receptors Attenuates Hypertrophy of Neonatal Rat Cardiomyocytes , 2014, Journal of cardiovascular pharmacology.
[7] Jing Zhao,et al. Preparation and Optimization of Resveratrol Nanosuspensions by Antisolvent Precipitation Using Box-Behnken Design , 2014, AAPS PharmSciTech.
[8] F. Apple,et al. Differential cardiotoxicity in response to chronic doxorubicin treatment in male spontaneous hypertension-heart failure (SHHF), spontaneously hypertensive (SHR), and Wistar Kyoto (WKY) rats. , 2013, Toxicology and applied pharmacology.
[9] Hope D. Anderson,et al. Reduced hemodynamic load aids low-dose resveratrol in reversing cardiovascular defects in hypertensive rats , 2013, Hypertension Research.
[10] D. Mcfadden,et al. Pterostilbene and cancer: current review. , 2012, The Journal of surgical research.
[11] P. Netti,et al. Metformin Prevents the Development of Chronic Heart Failure in the SHHF Rat Model , 2012, Diabetes.
[12] Hope D. Anderson,et al. Resveratrol prevents norepinephrine induced hypertrophy in adult rat cardiomyocytes, by activating NO-AMPK pathway. , 2011, European journal of pharmacology.
[13] I. Kapetanovic,et al. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats , 2011, Cancer Chemotherapy and Pharmacology.
[14] F. Villarroya,et al. Sirt1 acts in association with PPARα to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. , 2011, Cardiovascular research.
[15] Hope D. Anderson,et al. Suppression of endothelin-1-induced cardiac myocyte hypertrophy by PPAR agonists: role of diacylglycerol kinase zeta. , 2011, Cardiovascular research.
[16] A. Fenning,et al. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. , 2011, Current pharmaceutical biotechnology.
[17] L. Bertrand,et al. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. , 2011, Cardiovascular research.
[18] Fengjuan Yao,et al. Metformin attenuates ventricular hypertrophy by activating the AMP‐activated protein kinase–endothelial nitric oxide synthase pathway in rats , 2011, Clinical and experimental pharmacology & physiology.
[19] Hope D. Anderson,et al. Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. , 2010, American journal of hypertension.
[20] V. Dolinsky,et al. Calorie Restriction Prevents Hypertension and Cardiac Hypertrophy in the Spontaneously Hypertensive Rat , 2010, Hypertension.
[21] Yu-gang Dong,et al. Activation of AMPK inhibits cardiomyocyte hypertrophy by modulating of the FOXO1/MuRF1 signaling pathway in vitro , 2010, Acta Pharmacologica Sinica.
[22] T. Netticadan,et al. Resveratrol arrests and regresses the development of pressure overload- but not volume overload-induced cardiac hypertrophy in rats. , 2010, The Journal of nutrition.
[23] Hope D. Anderson,et al. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. , 2010, American journal of hypertension.
[24] S. Javadov,et al. Nitric oxide inhibits endothelin-1-induced neonatal cardiomyocyte hypertrophy via a RhoA-ROCK-dependent pathway. , 2009, Journal of molecular and cellular cardiology.
[25] K. Sunagawa,et al. Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis , 2009, Hypertension Research.
[26] Anita Y. M. Chan,et al. Resveratrol Prevents the Prohypertrophic Effects of Oxidative Stress on LKB1 , 2009, Circulation.
[27] F. Sakan,et al. Stilbenoids isolated from the seeds of Melinjo (Gnetum gnemon L.) and their biological activity. , 2009, Journal of agricultural and food chemistry.
[28] J. Cristol,et al. Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: involvement of osteopontin and oxidative stress. , 2008, Journal of agricultural and food chemistry.
[29] U. Laufs,et al. Metabolic Switch and Hypertrophy of Cardiomyocytes following Treatment with Angiotensin II Are Prevented by AMP-activated Protein Kinase* , 2008, Journal of Biological Chemistry.
[30] B. Viollet,et al. Resveratrol Inhibits Cardiac Hypertrophy via AMP-activated Protein Kinase and Akt* , 2008, Journal of Biological Chemistry.
[31] Hope D. Anderson,et al. Suppression of Cardiac Myocyte Hypertrophy by Conjugated Linoleic Acid , 2008, Journal of Biological Chemistry.
[32] Y. Ohgami,et al. Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity , 2008, Phytotherapy research : PTR.
[33] T. Netticadan,et al. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. , 2007, American journal of physiology. Heart and circulatory physiology.
[34] Dong Wang,et al. Long‐term activation of adenosine monophosphate‐activated protein kinase attenuates pressure‐overload‐induced cardiac hypertrophy , 2007, Journal of cellular biochemistry.
[35] V. Dolinsky,et al. Role of AMP-activated protein kinase in healthy and diseased hearts. , 2006, American journal of physiology. Heart and circulatory physiology.
[36] Joseph A. Baur,et al. Therapeutic potential of resveratrol: the in vivo evidence , 2006, Nature Reviews Drug Discovery.
[37] Mark A Sussman,et al. The Rac and Rho Hall of Fame: A Decade of Hypertrophic Signaling Hits , 2006, Circulation research.
[38] P. Pacaud,et al. Rho kinases in cardiovascular physiology and pathophysiology. , 2006, Circulation research.
[39] M. Drazner,et al. Does load-induced ventricular hypertrophy progress to systolic heart failure? , 2005, American journal of physiology. Heart and circulatory physiology.
[40] J. Bomser,et al. Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. , 2005, American journal of physiology. Heart and circulatory physiology.
[41] P. A. Oliver,et al. A Scaleable Synthesis of Fiduxosin , 2004 .
[42] Anita Y. M. Chan,et al. Activation of AMP-activated Protein Kinase Inhibits Protein Synthesis Associated with Hypertrophy in the Cardiac Myocyte* , 2004, Journal of Biological Chemistry.
[43] J. B. Magee,et al. Resveratrol, pterostilbene, and piceatannol in vaccinium berries. , 2004, Journal of agricultural and food chemistry.
[44] E. Olson,et al. Hypertrophy of the heart: a new therapeutic target? , 2004, Circulation.
[45] Yen-Ling Chen,et al. Inhibitory effect of resveratrol on angiotensin II-induced cardiomyocyte hypertrophy , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.
[46] Y. Akao,et al. Effects of hydroxystilbene derivatives on tyrosinase activity. , 2003, Biochemical and biophysical research communications.
[47] Tetsuro Ito,et al. Phenolic constituents of Gnetum klossii. , 2003, Journal of natural products.
[48] E. Blasi,et al. Structural, functional, and molecular characterization of the SHHF model of heart failure. , 2002, American journal of physiology. Heart and circulatory physiology.
[49] Han-Dong Sun,et al. Constituents of Gnetum montanum. , 2002, Fitoterapia.
[50] L. Tesson,et al. Stilbene content of mature Vitis vinifera berries in response to UV-C elicitation. , 2000, Journal of agricultural and food chemistry.
[51] K. S. Huang,et al. Stilbene dimers from the lianas of Gnetum hainanense. , 2000, Phytochemistry.
[52] C. Charpentier,et al. Occurrence of resveratrol and pterostilbene in age-old darakchasava, an ayurvedic medicine from India. , 1999, Journal of ethnopharmacology.
[53] A. Gerdes,et al. Myocyte remodeling during the progression to failure in rats with hypertension. , 1996, Hypertension.
[54] D. Levy,et al. The epidemiology of heart failure: the Framingham Study. , 1993, Journal of the American College of Cardiology.
[55] K. Nakajima,et al. Asymmetrical septal hypertrophy in patients with hypertension: A type of hypertensive left ventricular hypertrophy or hypertrophic cardiomyopathy combined with hypertension? , 1993, Clinical cardiology.
[56] D. Levy,et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.
[57] D. Gardner,et al. Tissue-specific determinants of human atrial natriuretic factor gene expression in cardiac tissue. , 1989, The Journal of biological chemistry.
[58] A. Zeidan,et al. Prevention of RhoA activation and cofilin-mediated actin polymerization mediates the antihypertrophic effect of adenosine receptor agonists in angiotensin II- and endothelin-1-treated cardiomyocytes , 2013, Molecular and Cellular Biochemistry.
[59] A. Marian. Contemporary treatment of hypertrophic cardiomyopathy. , 2009, Texas Heart Institute journal.
[60] A. Means,et al. Chutes and Ladders: the search for protein kinases that act on AMPK. , 2006, Trends in biochemical sciences.